VIR BIOTECHNOLOGY INC (VIR)

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

Oversold Conditions For Vir Biotechnology (VIR)

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational...

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

3 Highly Rated Biotech Stocks to Buy for 300% Gains

Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

Vir Biotechnology GAAP EPS of -$0.86 beats by $0.15, revenue of $16.79M beats by $10.24M (NASDAQ:VIR)

Vir Biotechnology reports beat on Q4 earnings: GAAP EPS of -$0.86, surpassing expectations by $0.15. Revenue of $16.79M beats estimates by $10.24M.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation.

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

JP Morgan cuts Vir to neutral, cites hepatitis drug franchise concerns (NASDAQ:VIR)

JP Morgan downgrades Vir Biotechnology (VIR) due in part to concerns over its viral hepatitis franchise and cash position. Read more here.

Vir Biotechnology to shed 12% of workforce as part of corporate restructuring (NASDAQ:VIR)

Vir Biotechnology (VIR) plans to cut its workforce by 12% and close two R&D facilities to focus on its hepatitis and antibody programs. Read more here.

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference

Commit To Purchase Vir Biotechnology At $7.50, Earn 14.9% Annualized Using Options

7 Small-Cap Stocks to Buy BEFORE the Year-End Rally

explore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Vir Biotechnology files for a mixed shelf offering (NASDAQ:VIR)

Read about Vir Biotechnology's mixed shelf offering as explained in their prospectus.

Vir Biotechnology GAAP EPS of -$1.22 beats by $0.03, revenue of $2.6M misses by $6.17M (NASDAQ:VIR)

Vir Biotechnology reports Q3 2023 financial results, with EPS beating estimates. Revenue misses due to lower sales and deferred revenue recognition.

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

3 Bill Gates Stocks to Buy for Billionaire-Like Returns

Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less.